Capricor Therapeutics - Public Comps and Valuation Multiples

Capricor Therapeutics Overview

About Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Founded

2005

HQ

Employees

160

Website

capricor.com

Sectors

Drug Development & Therapeutics
Regenerative Medicine
BioTech

Financials

LTM Revenue $5.9M

LTM EBITDA -$92.3M

EV

$202M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Capricor Therapeutics Financials

As of September 2025, Capricor Therapeutics reported last 12-month revenue of $5.9M and EBITDA of -$92.3M.

In the same period, Capricor Therapeutics achieved -$85.1M in LTM net income.

See Capricor Therapeutics valuation multiples based on analyst estimates

Capricor Therapeutics P&L

In the most recent fiscal year, Capricor Therapeutics reported revenue of $22.3M and EBITDA of -$41.1M.

Capricor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Capricor Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$5.9M	XXX	$22.3M	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$92.3M	XXX	-$41.1M	XXX	XXX	XXX
EBITDA Margin	-1576%	XXX	-185%	XXX	XXX	XXX
EBIT	-$88.6M	XXX	-$42.6M	XXX	XXX	XXX
EBIT Margin	-1513%	XXX	-191%	XXX	XXX	XXX
Net Profit	-$85.1M	XXX	-$40.5M	XXX	XXX	XXX
Net Margin	-1453%	XXX	-182%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Capricor Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $5.9M. EBITDA for the last twelve months was -$92.3M. In the most recent fiscal year, Capricor Therapeutics achieved $22.3M in revenue and -$41.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$5.9M	Analyst estimates available to subscribers	$22.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$92.3M	Analyst estimates available to subscribers	-$41.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-1575.7% EBITDA margin	Analyst estimates available to subscribers	-184.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$88.6M	Analyst estimates available to subscribers	-$42.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-1513.2% EBIT margin	Analyst estimates available to subscribers	-191.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$85.1M	Analyst estimates available to subscribers	-$40.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1452.9% net profit margin	Analyst estimates available to subscribers	-181.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Capricor Therapeutics

This financial data table provides comprehensive performance metrics for Capricor Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Capricor Therapeutics generated $5.9M in revenue over the last twelve months.
The company achieved -$92.3M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$85.1M.

Fiscal Year Performance

In the most recent fiscal year, Capricor Therapeutics reported $22.3M in total revenue.
Fiscal year EBITDA was -$41.1M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -184.7%.
Net profit margin reached -181.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Capricor Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Capricor Therapeutics Stock Performance

Capricor Therapeutics has current market cap of $324M, and EV of $202M.

Market Cap Evolution

Capricor Therapeutics Stock Data

As of October 13, 2025, Capricor Therapeutics's stock price is $7.

See Capricor Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$202M	$324M	XXX	XXX	XXX	XXX	$-1.92

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Capricor Therapeutics Valuation Multiples

Capricor Therapeutics's trades at 9.1x EV/Revenue multiple, and -4.9x EV/EBITDA.

See valuation multiples for Capricor Therapeutics and 15K+ public comps

Capricor Therapeutics Financial Valuation Multiples

As of October 13, 2025, Capricor Therapeutics has market cap of $324M and EV of $202M.

Equity research analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Capricor Therapeutics has a P/E ratio of -3.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$324M	XXX	$324M	XXX	XXX	XXX
EV (current)	$202M	XXX	$202M	XXX	XXX	XXX
EV/Revenue	34.6x	XXX	9.1x	XXX	XXX	XXX
EV/EBITDA	-2.2x	XXX	-4.9x	XXX	XXX	XXX
EV/EBIT	-2.3x	XXX	-4.8x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-3.8x	XXX	-8.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-4.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Capricor Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Capricor Therapeutics Margins & Growth Rates

Capricor Therapeutics's last 12 month revenue growth is 900%

Capricor Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Capricor Therapeutics's rule of 40 is 808% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Capricor Therapeutics's rule of X is 673% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Capricor Therapeutics and other 15K+ public comps

Capricor Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	900%	XXX	83%	XXX	XXX	XXX
EBITDA Margin	-1576%	XXX	-185%	XXX	XXX	XXX
EBITDA Growth	-36%	XXX	n/a	XXX	XXX	XXX
Rule of 40	808%	XXX	715%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	673%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	224%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	291%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial